A phase 1b trial (Clinicaltrials.gov, NCT01413022) blocked the recruitment of TAMs into the TME of PDAC using CCR2 inhibitor PF-04136309 in combination with chemotherapy FOLFIRINOX (oxaliplatin and irinotecan plus leucovorin and fluorouracil), achieving an objective tumor response in 49% (16) of 33 patients, with local tumor control in 97% (32) of 33 patients, showing better treatment response compared to the FOLFIRINOX-treated group [86]. This evidence concerns the gene CCR2 and neoplasm.